News | Vascular Access | January 31, 2017

Bard Recalls Halo One Thin-Walled Guiding Sheath Due to Sheath Separation, Kinking

Halo One Thin-Walled Guiding Sheath

The Halo One Thin-Walled Guiding Sheath.

January 31, 2017 — Bard Peripheral Vascular Inc. is recalling the Halo One Thin-Walled Guiding Sheath because the sheath body may separate from the sheath hub while removing the device from the patient's leg. The company also reports that the sheath may kink, and that its tip may become damaged during the procedure. The U.S, Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall.  

Bard said the use of affected sheaths may result in prolonged procedure times and on additional surgical intervention to remove detached components from the patient. The affected product may cause other serious adverse health consequences such as internal tears and perforation to arteries or veins, excessive bleeding and death. The Halo One Thin-Walled Guiding Sheath is used to introduce and/or guide the placement of interventional and diagnostic devices into veins and arteries through an incision made on a patient's leg.

On Jan. 10, 2017, Bard sent a medical device recall notification, which instructed consignees to stop using, or further distributing, any affected products. It also requested checks all inventory locations for affected product codes and lot numbers and to remove any affected products from the shelves. 

If an affected product has been used, Bard asked users to complete and return the "Recall and Effectiveness Check Form," which was attached to the notification, and which indicates no product will be returned.

The effected lots of the Halo One Thin-Walled Guiding Sheath involved in the recall include product codes HAL545, HAL590 and HAL510F. Lot numbers include: 50137556, 50137557, 50137598 50137682 50137723, 50137735, 50137875, 50137965, 50138274, 50138119, 50138118, 50138122, 50138273, 50138435, 50138437, 50138701, 50138439, 50137570, 50137770, 50137979, 50138696, 50137866, 50137924, 50138170 and 50138765. The manufacturing dates include product made between April 12, 2016 to July 7, 2016. Distribution dates include: June 24, 2016 to July 12, 2016. 

The recall included 101 units distributed in Arizona, Florida, Kansas, Louisiana, Maine, Michigan, Missouri, Nevada, New Hampshire, New York, Ohio, Texas, Utah, and Washington.

For more information, contact the firm's recall coordinator at (800) 321-4254, Option #2, Ext. 2501 (Monday - Friday 6 a.m. to 3 p.m. Mountain Standard Time), or by e-mail at [email protected]

For more information from the FDA: www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm538821.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init